Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, explains the importance of early intervention in myeloproliferative neoplasms (MPNs), and further highlights the value of identifying clonal hematopoiesis of indeterminate potential (CHIP) and other mutations, and informing patients on the risks associated with these. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.